PHARM-INTER: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
PHARM-INTER
Largest movements
- Current investments -€1.8m
no longer reported in 2025 (was €1.8m)
- Cash +€1.8m
up €1.8m (+131.4%), from €1.4m to €3.2m
mainly Current investments (+€1.8m) and Net result for the year (+€307,007)
- Reserves +€180,000
up €180,000 (+46.6%), from €386,391 to €566,391
- Other debts -€107,600
down €107,600 (-30.7%), from €350,000 to €242,400
- Profit (loss) carried forward -€102,993
down €102,993 (-86.0%), from €119,737 to €16,744
- Trade debts -€92,383
down €92,383 (-1.5%), from €6.3m to €6.2m
- Other operating charges +€355,630
up €355,630 (+5987.1%), from €5,940 to €361,569
- Gross operating margin +€300,460
up €300,460 (+34.4%), from €874,621 to €1.2m
- Financial income +€32,880
up €32,880 (+109.5%), from €30,020 to €62,899
- Staff costs +€26,573
up €26,573 (+9.9%), from €269,731 to €296,304
- Taxes -€16,904
down €16,904 (-10.5%), from €160,317 to €143,413
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €7,791,473 | €7,706,557 | -€84,916 | -1.1% |
| Formation expenses | 20 | - | €0 | = | |
| Fixed assets | 21/28 | €257,852 | €245,263 | -€12,589 | -4.9% |
| Tangible fixed assets | 22/27 | €63,732 | €51,143 | -€12,589 | -19.8% |
| Land and buildings | 22 | €36,074 | €30,463 | -€5,612 | -15.6% |
| Furniture and vehicles | 24 | €27,658 | €20,680 | -€6,977 | -25.2% |
| Financial fixed assets | 28 | €194,120 | €194,120 | = | 0.0% |
| Current assets | 29/58 | €7,533,621 | €7,461,294 | -€72,327 | -1.0% |
| Stocks and contracts in progress | 3 | €57,916 | €13,577 | -€44,339 | -76.6% |
| Stocks | 30/36 | €57,916 | €13,577 | -€44,339 | -76.6% |
| Amounts receivable within one year | 40/41 | €4,209,544 | €4,205,803 | -€3,741 | -0.1% |
| Trade receivables | 40 | €4,040,899 | €4,096,047 | +€55,148 | +1.4% |
| Other amounts receivable | 41 | €168,645 | €109,756 | -€58,889 | -34.9% |
| Current investments | 50/53 | €1,840,000 | - | -€1.8m | |
| Cash at bank and in hand | 54/58 | €1,397,237 | €3,233,574 | +€1.8m | +131.4% |
| Deferred charges and accrued income | 490/1 | €28,924 | €8,340 | -€20,584 | -71.2% |
| Total equity and liabilities | 10/49 | €7,791,473 | €7,706,557 | -€84,916 | -1.1% |
| Equity | 10/15 | €856,128 | €933,135 | +€77,007 | +9.0% |
| Contributions | 10/11 | €350,000 | €350,000 | = | 0.0% |
| Outside capital | 11 | €350,000 | - | -€350,000 | |
| Other | 1109/19 | €350,000 | - | -€350,000 | |
| Reserves | 13 | €386,391 | €566,391 | +€180,000 | +46.6% |
| Distributable reserves | 133 | €386,391 | €566,391 | +€180,000 | +46.6% |
| Profit (loss) carried forward | 14 | €119,737 | €16,744 | -€102,993 | -86.0% |
| Amounts payable | 17/49 | €6,935,345 | €6,773,422 | -€161,923 | -2.3% |
| Amounts payable within one year | 42/48 | €6,935,345 | €6,773,422 | -€161,923 | -2.3% |
| Current portion of amounts payable after more than one year | 42 | €2,806 | - | -€2,806 | |
| Financial debts | 43 | €220,000 | €251,526 | +€31,526 | +14.3% |
| Credit institutions | 430/8 | €220,000 | €251,526 | +€31,526 | +14.3% |
| Trade debts | 44 | €6,292,822 | €6,200,439 | -€92,383 | -1.5% |
| Suppliers | 440/4 | €6,292,822 | €6,200,439 | -€92,383 | -1.5% |
| Taxes, remuneration and social security | 45 | €69,718 | €79,057 | +€9,339 | +13.4% |
| Taxes | 450/3 | €34,408 | €40,638 | +€6,230 | +18.1% |
| Remuneration and social security | 454/9 | €35,310 | €38,419 | +€3,109 | +8.8% |
| Other amounts payable | 47/48 | €350,000 | €242,400 | -€107,600 | -30.7% |
| Remuneration, social security and pensions | 62 | €269,731 | €296,304 | +€26,573 | +9.9% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €15,426 | €12,589 | -€2,837 | -18.4% |
| Other operating charges | 640/8 | €5,940 | €361,569 | +€355,630 | +5987.1% |
| Gross operating margin | 9900 | €874,621 | €1,175,081 | +€300,460 | +34.4% |
| Operating profit (loss) | 9901 | €583,524 | €504,619 | -€78,905 | -13.5% |
| Financial income | 75/76B | €30,020 | €62,899 | +€32,880 | +109.5% |
| Recurring financial income | 75 | €30,020 | €62,899 | +€32,880 | +109.5% |
| Financial charges | 65/66B | €108,516 | €117,098 | +€8,582 | +7.9% |
| Recurring financial charges | 65 | €108,516 | €117,098 | +€8,582 | +7.9% |
| Profit (loss) for the period before taxes | 9903 | €505,027 | €450,420 | -€54,607 | -10.8% |
| Income taxes | 67/77 | €160,317 | €143,413 | -€16,904 | -10.5% |
| Profit (loss) for the period | 9904 | €344,710 | €307,007 | -€37,703 | -10.9% |
| Profit (loss) for the period to be appropriated | 9905 | €344,710 | €307,007 | -€37,703 | -10.9% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 29 September 2026 via checked.be.